Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data ...

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ...

“IO Biotech continues to make meaningful progress developing novel cancer therapies that are designed to address significant unmet needs in melanoma and other hard-to-treat cancers, and we are ...

"IO Biotech continues to make meaningful progress developing novel cancer therapies that are designed to address significant unmet needs in melanoma and other hard-to-treat cancers, and we are ...

IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR ...

IO Biotech Stock Up 1.0% NASDAQ IOBT opened at $1.00 on Monday. The firm’s 50-day simple moving average is $0.95 and its two-hundred day simple moving average is $0.94.

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical firm with a market capitalization of approximately $61 million, has presented new preclinical data on two therapeutic cancer ...

(Abstract #2241) IO170, also developed using IO Biotech’s T-win® platform, demonstrated significant tumor growth inhibition in breast and prostate cancer mouse models. The TGF- β-directed ...